PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24044936-0	2013	Synthesis of conformationally constrained gamma-D-glutamyl-meso-diaminopimelic acid derivatives as ligands of nucleotide-binding oligomerization domain protein 1 (Nod1).	N(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acid	42-83	nucleotide binding oligomerization domain containing 1	Homo sapiens	110-161	
29165176-3	2017	Nucleotide-binding oligomerization domain-containing protein 1 and 2 (NOD1 and NOD2) are components of NLR family, and ligands of these factors are gamma-D-glutamyl-meso-diaminopimelic acid (iE-DAP) and muramyl dipeptide (MDP), respectively.	N(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acid	148-189	nucleotide binding oligomerization domain containing 1	Homo sapiens	0-68	
29165176-3	2017	Nucleotide-binding oligomerization domain-containing protein 1 and 2 (NOD1 and NOD2) are components of NLR family, and ligands of these factors are gamma-D-glutamyl-meso-diaminopimelic acid (iE-DAP) and muramyl dipeptide (MDP), respectively.	N(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acid	148-189	nucleotide binding oligomerization domain containing 1	Homo sapiens	70-74	
32148412-5	2020	Methods: EndMT was examined under an inflammatory condition mediated by the NOD1 agonist, gamma-d-glutamyl-meso-diaminopimelic acid (iE-DAP), treatment in human umbilical vein endothelial cells.	N(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acid	90-131	nucleotide binding oligomerization domain containing 1	Homo sapiens	76-80	
24044936-0	2013	Synthesis of conformationally constrained gamma-D-glutamyl-meso-diaminopimelic acid derivatives as ligands of nucleotide-binding oligomerization domain protein 1 (Nod1).	N(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acid	42-83	nucleotide binding oligomerization domain containing 1	Homo sapiens	163-167	
21677137-6	2011	Activation of Nod1 by its agonist, bacterial gamma-D-glutamyl-meso-diaminopimelic acid (iE-DAP), in term trophoblast cultures induced a proinflammatory cytokine profile, characterized by elevated levels of secreted IL-6, GRO-alpha, and MCP-1, when compared with the control.	N(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acid	45-86	nucleotide binding oligomerization domain containing 1	Homo sapiens	14-18	
23524653-3	2013	Eosinophils constitutively expressed NOD1,2 but exhibited nonsignificant responses to release chemokines upon the stimulation by NOD1 ligand gamma-D-glutamyl-meso-diaminopimelic acid (iE-DAP) and NOD2 ligand muramyl dipeptide (MDP).	N(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acid	141-182	nucleotide binding oligomerization domain containing 1	Homo sapiens	129-133	
21924184-7	2011	In addition, human dental pulp fibroblasts were stimulated with NOD-1 agonist gamma-D-glutamylmeso-diaminopimelic acid.	N(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acid	78-118	nucleotide binding oligomerization domain containing 1	Homo sapiens	64-69	
19260860-4	2009	METHOD OF STUDY: The effect of Nod1 activation on trophoblast cells was determined by analyzing the cytokine response following treatment with gamma-D-glutamyl-meso-diaminopimelic acid (iE-DAP).	N(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acid	143-184	nucleotide binding oligomerization domain containing 1	Homo sapiens	31-35	
20002790-8	2010	No expression of NOD1 was found in isolated neutrophils and stimulation with the NOD1 ligand gamma-d-glutamyl-meso-diaminopimelic acid induced no signs of activity.	N(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acid	93-134	nucleotide binding oligomerization domain containing 1	Homo sapiens	81-85	
17322292-2	2007	Previous studies suggested that the recognition core of Nod1 stimulatory molecules is gamma-D-glutamyl-meso-diaminopimelic acid (iE-DAP), but the identity of the major Nod1 stimulatory molecule produced by bacteria remains unknown.	N(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acid	86-127	nucleotide binding oligomerization domain containing 1	Homo sapiens	56-60	
18474668-7	2008	Exposure to gamma-iE-DAP at the apical surface of differentiated, polarized cultures resulted in activation of the innate immune response in an NOD1- and RIP2-dependent manner, resulting in release of IL-6 and IL-8.	N(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acid	12-24	nucleotide binding oligomerization domain containing 1	Homo sapiens	144-148	
17621561-5	2007	We also synthesized potent NOD1 agonists, which showed several hundred-fold stronger activity than gamma-D-glutamyl-meso-diaminopimelic acid (iE-DAP).	N(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acid	99-140	nucleotide binding oligomerization domain containing 1	Homo sapiens	27-31	
17005562-8	2006	Functionally, CENTB1 overexpression inhibited NOD1- and NOD2-dependent activation of NF-kappaB, whereas small inhibitory RNA against CENTB1 increased NF-kappaB activation following NOD1- or NOD2-mediated recognition of the bacterial components gamma-d-glutamyl-meso-diaminopimelic acid and muramyl dipeptide, respectively.	N(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acid	244-285	nucleotide binding oligomerization domain containing 1	Homo sapiens	181-185